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Improving the chance of cure
of follicular lymphoma by
combining immunotherapy
and radioimmunotherapy based
on anti-CD20 antibodies?
The recently published ESMO lymphoma treatment guidelines
[1] recommend the use of single-agent rituximab as an option
in follicular lymphoma (FL) for avoiding the side-effects of
chemotherapy. We may add to this point that results from the
literature as well as our own observation show that radiolabeled
anti-CD20 radioimmunotherapy (RIT), as a treatment
consisting of two injections given at a 7-day interval, can lead
to high rates of complete responses (CRs) and over 10 years
recurrence-free survival in a signiﬁcant percentage of patients.
These results, conﬁrmed at the molecular level in a high
percentage of cases, were observed with treatment at ﬁrst line,
in consolidation and in relapsed/refractory indolent lymphoma
[2–4]. They favorably compare with the above-mentioned
results of single-agent rituximab [1] shown to induce long-term
remissions of FL and to represent a well-tolerated maintenance
therapy [5].
Surprisingly, these two very efﬁcient forms of B cell-speciﬁc
anti-CD20-mediated therapies have never been tested in
combination in a well-designed clinical trial of FL. In the most
recent randomized, phase III trial of untreated FL, RIT, and
rituximab treatments were compared, but they were both
associated with the same combination of cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP)
chemotherapy [6]. The two arms gave excellent and similar
results, but the two antibody-mediated therapies could not be
evaluated individually or in combination.
The combination of these two forms of anti-CD20
immunotherapies might increase the CR with less side-effects
than chemotherapy and preserve the T cells’ immune defenses.
Indeed, the positive role of T cells’ responses against
lymphomas has been well documented in experimental and
clinical investigations, including idiotype vaccination and
allogeneic bone marrow transplantation [7]. Furthermore, the
fact that the two approved anti-CD20 antibodies,
tositumomab and ibritumomab, are of murine origin includes
tumor targeting of new antigens, which can be recognized in
their processed form by the patient’s T lymphocytes [8]. The
important role of effector cells from innate immunity, such as
natural killer (NK) cells, is well known both for antibody-
dependent cell mediated cytotoxicity and for the prevention
of recurrence. Interestingly, it was recently shown that
injection of rituximab resulted in the activation of the NK
cells in patients with the high-afﬁnity Fcγ receptor genetic
polymorphism [9].
The strong efﬁcacy of RIT cannot be entirely explained by
the relatively low radiation dose to the tumor cells or by the
associated administration of unlabeled anti-CD20 antibody,
but probably by the combination of both that associate with
the patient’s preserved T cells immunity. It has been recently
reported that irradiated lymphoma cells have an increased
immunogenicity and that irradiation of lymphoma,
accompanied by systemic delivery of a TLR7 agonist, can
induce durable antitumor immune response in murine
syngeneic lymphoma models [10].
In conclusion, we think that in FL the combination of these
two antibody-mediated biotherapies might produce a synergy
leading to higher CRs and longer disease-free survival rates
than each single modality and, thanks to the preservation of
the patient’s immune system, improve the chance of cure.
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Spin and bias: the tip of the
iceberg
Vera-Badillo et al. [1] have to be congratulated for uncovering
a problem with reporting of trial results, a problem that
distorts the record, impedes inference, and can lead to ﬂawed
medical decisions. It is important to note that the associated
problems of biased reporting and spin remain problems no
matter how often they occur; once is once too often.
Hence, the proportions presented should be understood in
this context, and we should not lose sight of the forest for the
trees. Nevertheless, I would propose that the proportions
presented should have been based on the subset of 30 trials
with complete information (including the primary end point
that was prospectively speciﬁed), either instead of or in
addition to the proportions that were presented based on the
full sample of 164 trials.
We are told, for example, that 7 of the 30 trials reported a
different primary end point, and we can only imagine that this
switch would have occurred in a higher proportion of the other
134 trials, given that the authors of those trials did not need to
worry about getting caught. This uncertainty undermines our
ability to offer credible statements about how often these 134
trials were biased or spun. But we do see bias in at least 7 of
the 30, and have to wonder how often there was bias and/or
spin in the other 23 among these 30. This would be a rather
telling statistic, arguably more telling than the one based on
the full set of 164.
Moreover, the problems reported, though certainly of
substantial importance, may still represent only the tip of the
iceberg, and not only because we can check for changes in the
primary end point in only 30 of the 164 trials. Beyond this, we
also have the fact that there are many more biases, far too
many to list here, that may have gone into producing spurious
statistical signiﬁcance in the primary end point. So what we
have here is a best-case scenario, and a comprehensive look at
spin, plus bias as deﬁned here, plus bias deﬁned more broadly,
might reveal a far worse state of affairs in the trial research
record [2].
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iceberg
We thank Dr Berger for his kind comments on our study
[1]. Our primary aim was to determine the frequency of
spin and bias applied to misreporting the primary end
point, and failure to include a description of toxicity in the
abstract. To focus the ﬁndings of our research on only 30
trials with complete reporting of the primary end point
(only 18% of the total sample) would perhaps have allowed
us to separate spin (i.e. where complete information is
provided but results are presented in such a way as to
make them appear to be more favourable to the
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